BRIEF-Lantheus Presents Results From The Primary Analysis Of Phase 3 Pivotal Splash Trial

Reuters09-15

Sept 15 (Reuters) - Lantheus Holdings Inc :

* LANTHEUS PRESENTS RESULTS FROM THE PRIMARY ANALYSIS OF PHASE 3 PIVOTAL SPLASH TRIAL IN PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DURING ESMO CONGRESS 2024

* LANTHEUS HOLDINGS - STUDY MET ITS PRIMARY ENDPOINT

* LANTHEUS HOLDINGS INC - OVERALL RESPONSE RATE WAS 38.1% VERSUS. 12.0% FOR ARPI SWITCH ARM

* LANTHEUS HOLDINGS INC - OVERALL SURVIVAL DATA CONTINUE TO MATURE

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2467883992?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-15 20:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2467883992","market":"us","top_or_hot":-1,"title":"BRIEF-Lantheus Presents Results From The Primary Analysis Of Phase 3 Pivotal Splash Trial","media":"Reuters","content":"<html><body><p>Sept 15 (Reuters) - Lantheus Holdings Inc   :</p><p>   * LANTHEUS PRESENTS RESULTS FROM THE PRIMARY ANALYSIS OF PHASE 3 PIVOTAL SPLASH TRIAL IN PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DURING ESMO CONGRESS 2024</p><p>   * LANTHEUS HOLDINGS - STUDY MET ITS PRIMARY ENDPOINT</p><p>   * LANTHEUS HOLDINGS INC - OVERALL RESPONSE RATE WAS 38.1% VERSUS. 12.0% FOR ARPI SWITCH ARM</p><p>   * LANTHEUS HOLDINGS INC - OVERALL SURVIVAL DATA CONTINUE TO MATURE</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Lantheus Presents Results From The Primary Analysis Of Phase 3 Pivotal Splash Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Lantheus Presents Results From The Primary Analysis Of Phase 3 Pivotal Splash Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-15 20:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sept 15 (Reuters) - Lantheus Holdings Inc   :   * LANTHEUS PRESENTS RESULTS FROM THE PRIMARY ANALYSIS OF PHASE 3 PIVOTAL SPLASH TRIAL IN PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0348723411.USD","symbol_name":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2467883992","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2467883992","pubTimestamp":1726404887,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Sept 15  - Lantheus Holdings Inc   :   * LANTHEUS PRESENTS RESULTS FROM THE PRIMARY ANALYSIS OF PHASE 3 PIVOTAL SPLASH TRIAL IN PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DURING ESMO CONGRESS 2024   * LANTHEUS HOLDINGS - STUDY MET ITS PRIMARY ENDPOINT   * LANTHEUS HOLDINGS INC - OVERALL RESPONSE RATE WAS 38.1% VERSUS. 12.0% FOR ARPI SWITCH ARM   * LANTHEUS HOLDINGS INC - OVERALL SURVIVAL DATA CONTINUE TO MATURESource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品","BK4588":"碎股","IE00BMPRXQ63.HKD":"NEUBERGER BERMAN NEXT GENERATION CONNECTIVITY FUND \"A\" (HKDHDG) ACC","BK4141":"半导体产品","LNTH":"Lantheus Holdings, Inc.","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC"},"translate_title":"简介-Lantheus展示了3期关键Splash试验的主要分析结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LNTH":1},"content_text":"Sept 15 (Reuters) - Lantheus Holdings Inc   :   * LANTHEUS PRESENTS RESULTS FROM THE PRIMARY ANALYSIS OF PHASE 3 PIVOTAL SPLASH TRIAL IN PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DURING ESMO CONGRESS 2024   * LANTHEUS HOLDINGS - STUDY MET ITS PRIMARY ENDPOINT   * LANTHEUS HOLDINGS INC - OVERALL RESPONSE RATE WAS 38.1% VERSUS. 12.0% FOR ARPI SWITCH ARM   * LANTHEUS HOLDINGS INC - OVERALL SURVIVAL DATA CONTINUE TO MATURESource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Business Data","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2467883992"}